公开(公告)号：US20210215716A1

公开(公告)日：2021-07-15

申请号：US17181386

申请日：2021-02-22

Applicant: Roche Diagnostics Operations, Inc. ,  Universiteit Maastricht ,  Academisch Ziekenhuis Maastricht

Inventor： Peter Kastner ,  Manuel Dietrich ,  André Ziegler ,  Ursula-Henrike Wienhues-Thelen ,  Vinzent Rolny ,  Ulrich Schotten

IPC: G01N33/68 ,  C07K16/18 ,  G16B25/10

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of SPON-1 in a sample from the subject, and comparing the amount of SPON-1 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to methods for the prediction of stroke based on the amount of SPON-1.

公开(公告)号：US20230341419A1

公开(公告)日：2023-10-26

申请号：US18021047

申请日：2021-08-12

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  David Conen ,  Stefan Osswald ,  Michael Kuehne ,  Peter Kastner

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2871 ,  G01N2800/52 ,  G01N2800/50

Abstract: The present invention relates to a method for assessing whether a subject has experienced one or more silent infarcts in a subject, said method comprising a) determining the amount of the biomarker ESM-1 in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) assessing whether a subject has experienced one or more silent infarcts. The present invention further relates to a method for predicting silent infarcts and/or cognitive decline, and methods for assessing and monitoring of the extent of silent small and large noncortical and cortical infarcts in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20230176077A1

公开(公告)日：2023-06-08

申请号：US17912776

申请日：2021-03-18

Applicant: Universiteit Maastricht ,  Academisch Ziekenhuis Maastricht ,  Roche Diagnostics Operations, Inc.

Inventor： Peter Kastner ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  André Ziegler ,  Manuel Dietrich ,  Ulrich Schotten

IPC: G01N33/68

CPC classification number: G01N33/6896 ,  G01N2800/2871 ,  G01N2800/326 ,  G01N2800/50 ,  G01N2333/9121

Abstract: The present invention relates to a method for aiding in the prediction of stroke and/or dementia in a subject, said method comprising a) determining the amount of the biomarker RET (Rearranged during transfection) in a sample from the subject, b) comparing the amount determined in step a) to a reference, and c) aiding in the prediction of stroke and/or dementia. The present invention further relates to a method for aiding in the assessment of the extent of white matter lesions in a subject, a method for aiding in the assessment whether a subject has experienced one or more silent strokes and to a method for aiding in the diagnosis of atrial fibrillation in a subject. Further encompassed by the present invention are the corresponding uses.

公开(公告)号：US20210156875A1

公开(公告)日：2021-05-27

申请号：US17161998

申请日：2021-01-29

Applicant: Roche Diagnostics Operations, Inc. ,  Universitaet Maastricht ,  Academisch Ziekenhuis Maastricht

Inventor： Johann Karl ,  Peter Kastner ,  Roberto Latini ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  Andre Ziegler ,  Manuel Dietrich ,  Jennifer Meessen ,  Ulrich Schotten

IPC: G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of DKK3 in a sample from the subject, and comparing the amount of DKK3 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure and/or at least one structural or functional abnormality of the heart associated with heart failure.

公开(公告)号：US20180292410A1

公开(公告)日：2018-10-11

申请号：US16008550

申请日：2018-06-14

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Farshid Dayyani ,  Friedemann Krause ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Vinzent Rolny ,  Sandra Rutz ,  Thomas Muley ,  Felix Herth ,  Julia Riedlinger

IPC: G01N33/574

Abstract: The present disclosure relates to a method of detecting a relapse of a lung adenocarcinoma in an individual based on marker human epididymis protein 4 (HE4) and optionally Cytokeratin-19 fragments (Cyfra21-1) as well as the use of a marker in the in vitro assessment of a relapse of a lung adenocarcinoma.

公开(公告)号：US20230358750A1

公开(公告)日：2023-11-09

申请号：US18352183

申请日：2023-07-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Anika Mang ,  Thomas Muley ,  Vinzent Rolny ,  Birgit Wehnl

IPC: G01N33/574

CPC classification number: G01N33/57423 ,  G01N2333/4742 ,  G01N2333/4725 ,  G01N2333/70596

Abstract: The present invention relates to an in vitro method for assessing the risk of non-small cell lung carcinoma (NSCLC) disease progression for a subject classified to have stable disease under an ongoing NSCLC treatment regime. The method involves determining the level of CYFRA 21-1 and/or the level of CA 125 in a sample obtained from the subject; and comparing (i) the determined level of CYFRA 21-1 to a CYFRA 21-1 cut-off level, (ii) the determined level of CA 125 to a CA 125 cut-off level, or (iii) a score taking into account the determined level of CYFRA 21-1 and/or the determined level of CA 125 to a cut-off score. The method of the invention further allows for assessing whether the subject responds to the ongoing treatment and/or whether the treatment regime should be maintained or modified. The invention also provides for corresponding uses, computer-implemented methods and computer program products.

公开(公告)号：US20230095167A1

公开(公告)日：2023-03-30

申请号：US17801469

申请日：2021-02-19

Applicant: Universiteit Maastricht ,  Academisch Ziekenhuis Maastricht ,  Roche Diagnostics Operations, Inc.

Inventor： Alfred Engel ,  Michael Gerg ,  Ute Jucknischke ,  Johann Karl ,  Peter Kastner ,  Thomas Meier ,  Lars Hillringhaus ,  Ulrich Schotten ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen ,  André Ziegler ,  Roberto Latini ,  Jennifer Marie Theresia Anna Meessen

IPC: G01N33/74 ,  G01N33/68

Abstract: The present invention relates to a method for assessing atrial fibrillation in a subject, said method comprising the steps of determining the amount of BMP10 in a sample from the subject, and comparing the amount of BMP10 to a reference amount, whereby atrial fibrillation is to be assessed. Moreover, the present invention relates to a method for diagnosing heart failure based on the determination of BMP 10 in a sample from a subject. Further, the present invention relates to a method for predicting the risk of a subject of hospitalization due to heart failure based on the determination of a BMP10-type peptide in a sample from a subject. The present invention further pertains to antibodies which bind to one or more BMP10-type peptides such as NT-proBMP10.

公开(公告)号：US20200371114A1

公开(公告)日：2020-11-26

申请号：US16721112

申请日：2019-12-19

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Roberto Latini ,  Serge Masson ,  Dirk Block ,  Christian Zaugg ,  Thomas Dieterle ,  Edelgard Kaiser ,  Johann Karl ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen

IPC: G01N33/68

Abstract: The present invention relates to a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from the group consisting of a BNP-type peptide, IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject. The method may further encompass the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy. Further envisaged by the present invention are devices adapted to carry out the present invention.

公开(公告)号：US10557858B2

公开(公告)日：2020-02-11

申请号：US15581587

申请日：2017-04-28

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Roberto Latini ,  Serge Masson ,  Dirk Block ,  Christian Zaugg ,  Thomas Dieterle ,  Edelgard Kaiser ,  Johann Karl ,  Vinzent Rolny ,  Ursula-Henrike Wienhues-Thelen

IPC: G01N33/50 ,  G01N33/68

Abstract: Described is a method for predicting the risk of a subject of rapidly progressing to chronic heart failure and/or of hospitalization due to chronic heart failure and/or death. The method is based on the determination of at least one biomarker selected from B-type natriuretic peptide (BNP) or N-terminal pro B-type natriuretic peptide (NT-proBNP), IGFBP7 (IGF binding protein 7), a cardiac Troponin, soluble ST2 (sST2), FGF-23 (Fibroblast Growth Factor 23), and Growth Differentiation Factor 15 (GDF-15), in a sample of a subject along with the assessment of the presence or absence of (i) abnormal midwall fractional shortening or (ii) left ventricular hypertrophy.

公开(公告)号：US20180231557A1

公开(公告)日：2018-08-16

申请号：US15952731

申请日：2018-04-13

Applicant: Roche Diagnostics Operations, Inc.

Inventor： Friedemann Krause ,  Vinzent Rolny ,  Farshid Dayyani ,  Achim Escherich ,  Birgit Wehnl ,  Ying He ,  Julia Riedlinger ,  Felix Herth ,  Thomas Muley

IPC: G01N33/574

CPC classification number: G01N33/57423 ,  G01N33/57484 ,  G01N2333/4742 ,  G01N2333/70596

Abstract: The present disclosure relates to a method of identifying an individual having non-small cell lung carcinoma as to be treated by chemotherapy based on marker molecules cytokeratin-19 fragments (CYFRA 21-1) and carcinoembryonic antigen (CEA) as well as the use of the marker molecules for the identification of an individual to be treated by chemotherapy.